Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap178.15M
Enterprise Value128.15M
Trailing P/E1.06
Forward P/E0.64
CHRS
(NASDAQ)Coherus Oncology, Inc.
$1.51-- (--)
Loading... - Market loading
Coherus Oncology (CHRS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)4.22
Forward Price/Sales2.64
Price/Book (mrq)2.92
Price/Tangible Book (mrq)12.06
PEG Ratio0.02
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue3.04
EV/Earnings0.76
EV/EBITDA-0.74
EV/EBIT-0.73
EV/FCF-0.93
Stock Price
Current price, 52-week range, and moving averages
Current Price$1.51
1-Day Change2.03%
52-Week High$2.62
52-Week Low$0.71
52-Week Change91.18%
YTD Change10.22%
1-Year Change95.37%
50-Day MA$1.75
200-Day MA$1.54
Avg Volume (30 day)1.29M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding120.37M
Book Value per Share$0.51
Net Cash per Share$0.42
FCF per Share$-1.15
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin67.24%
EBITDA Margin (ttm)-409.10%
EBIT Margin (ttm)-417.11%
Operating Margin (ttm)-429.51%
Pretax Margin (ttm)-434.23%
Profit Margin (ttm)397.99%
FCF Margin (ttm)-328.45%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)275.08%
Return on Assets (ttm)64.97%
Return on Invested Capital (ttm)-1261.71%
Return on Capital Employed (ttm)-151.03%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue42.17M
Gross Profit28.36M
Operating Income-181.13M
Pretax Income-183.12M
Net Income167.84M
EBITDA-172.53M
EBIT-175.91M
Diluted EPS$1.43
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-138.51M
Free Cash Flow-138.51M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-69.33%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)258.34M
Cash & Securities (mrq)88.88M
Net Cash (mrq)50.00M
Net Cash per Share$0.42
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)38.88M
Working Capital (mrq)64.83M
Total Equity (mrq)61.01M
Book Value per Share$0.51
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)1.46
Quick Ratio (mrq)1.43
Debt/Equity (mrq)0.64
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield94.21%
FCF Yield-77.75%
Buyback Yield-4.49%
Total Shareholder Yield-4.49%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-8.74
Piotroski F-Score6/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$75.94
Lynch Upside/Downside4929.38%
Graham Number$4.04
Graham Upside/Downside167.72%
Frequently Asked Questions About Coherus Oncology Statistics
What are the key financial metrics for CHRS?
Coherus Oncology, Inc. (CHRS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is CHRS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Coherus Oncology is overvalued or undervalued.
How do I read CHRS's profitability ratios?
Coherus Oncology's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do CHRS's debt ratios indicate?
The financial health section shows Coherus Oncology's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is CHRS's dividend analysis?
The dividend section covers Coherus Oncology's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.